InveniAI® LLC has formed a strategic partnership with TB Alliance, a non-profit organization dedicated to the discovery, development, and delivery of better, faster-acting and affordable tuberculosis (TB) drugs.
TB Alliance will make use of InveniAI’s AI and machine learning platform, AlphaMeld®, to identify and accelerate transformative therapies for the management, treatment, and cure of TB, which remains the world’s top infectious disease killer.